APEX has completed patient dosing in our STEP-52 study evaluating APEX-52 #microdose #psilocybin in treating #depression in patients with diagnosed #PTSD and the stability of symptoms transitioning from illicit unregulated psilocybin to APEX-52! Details: bit.ly/3TSWpo0

Meet Tyler Powell, APEX Co-Founder & CEO! An entrepreneur by trade with an extensive finance background, Tyler identifies areas with substantial unmet needs and builds collaborative teams with diverse experience that believe in the mission. Learn more: bit.ly/3yBzzYo

Incredible exclusive feature of APEX in Benzinga by Lara Goldstein with a great breakdown of our new macrodose phase 2b clinical trial trial approval and commercial strategy, highlighting the team’s expertise and unique opportunity in the market: bit.ly/3KLrDJC

On the heels of our recent Health Canada and PHAC approval of the SUMMIT-90 macrodose trial with assisted psychotherapy, the AMA highlights the medical community's growing support for psychedelic treatment and validates APEX's investment in this area: bit.ly/42kwb0L

Another step forward cementing APEX’s ability to execute a robust clinical pipeline and Early Access Program in Canada and the US with drug supply established in both markets. bit.ly/3oSpqVT #Depression #PTSD #Biotech #Pharmaceuticals #Psilocybin #psychedelics

Great article from Lara Goldstein at Benzinga on APEX’s latest milestone. Read more here: bit.ly/3X392OM #Depression #PTSD #Biotech #Pharmaceuticals #Psilocybin #psychedelics #anxiety

Tune in to CNN Sunday 8pm EST for “Magic Mushrooms: Can They Change Your Mind?” with CNN’s David Culver on the Whole Story with Anderson Cooper as they explore the therapeutic benefits of medically supervised consumption of #psilocybin. cnn.it/3JjSkVU

More encouraging regulatory support for #psychedelic medicines with Australia officially allowing authorized psychiatrists to prescribe #psilocybin for TRD and MDMA for the treatment of #PTSD as of July 1st. Read more here: cnn.it/44zKaks

Already known to many taking the treatment, a new paper shows “emotional blunting” is found in patients taking an #SSRI whereas those taking #psilocybin experienced significant improvement in depression with minimal effect on emotional response. Details: bit.ly/47kSI0Q

APEX welcomes two distinguished executives to our team. Dr. Mark Johnston, a seasoned psychiatrist with strong expertise in Veteran health joins as our CMO alongside Greg Rutherford, a global pharmaceutical commercialization expert as CCO. Learn more: bit.ly/47m0aZD

This is an exciting step forward for Canadian Veterans and #psilocybin access. We are excited to support Kelsi's SAP approval, offer hope, open the door for new ways to heal and tackle the #mentalhealth crisis plaguing this community. bit.ly/3PsVAAu The Kelsi Sheren Perspective

This is an exciting step forward for Canadian Veterans and #psilocybin access. We are excited to support Kelsi's SAP approval, offer hope, open the door for new ways to heal and tackle the #mentalhealth crisis plaguing this community. The Kelsi Sheren Perspective bit.ly/3PsVAAu

The APEX Early Access Program (EAP) is officially launched! We look forward to expanding the program to even more Canadian Veterans. View our press release for more info: bit.ly/40kqXSG #Psilocybin #MentalHealth #Veterans #Depression #PTSD

Thank you Senate Subcommittee on Veterans Affairs for the push toward Veteran psychedelic access & research. APEX is grateful to have been included in the report alongside @kelsie_sheren, who accessed APEX-90 through Health Canada and PHAC’s Special Access Program: bit.ly/47kZDGZ

A Roll Call article highlights growing momentum in Congress supporting exploring #psychedelic treatments for #PTSD among servicemembers & vets. Current legislative efforts are spearheaded by advocates like Reps. Alexandria Ocasio-Cortez & Daniel Crenshaw: bit.ly/3Gk2O5E

US Veterans Affairs (VA) will fund research in #psilocybin and #MDMA for treating PTSD and depression! As a Veteran focused company, we applaud the VA for this huge milestone and step forward towards broader access #MentalHealth h #VeteransHealth bit.ly/3HaaLuG

Another signal of growing support from US regulators towards access to psilocybin therapies state after state! #HealthcareInnovation #MentalHealth #PsychedelicResearch #Psilocybin

APEX has received its Dealers Licence from Health Canada allowing direct psilocybin sales through multiple channels, paving the way to both access and revenue in Canada: bit.ly/3wla0wQ #HealthcareInnovation #MentalHealth #PsychedelicResearch #VeteransHealth #Psilocybin

APEX filed a US patent protecting our uniquely formulated capsule paving the way for strong and sustainable commercial sales. Read more here: prn.to/3TqJzia #HealthcareInnovation #MentalHealth #PsychedelicResearch #VeteransHealth #Psilocybin

Great article featuring APEX by CBC News highlighting the upcoming launch of our 160 patient SUMMIT-90 clinical trial evaluating APEX-90 alongside assisted psychotherapy. Pre-screening is already underway at ptsdresearch.ca! cbc.ca/news/canada/lo…